Recent advances in targeted drug delivery systems for multiple myeloma

IF 10.5 1区医学 Q1 CHEMISTRY, MULTIDISCIPLINARY

Journal of Controlled Release Pub Date : 2024-10-12 DOI:10.1016/j.jconrel.2024.10.003

引用次数: 0

Abstract

Despite significant therapeutic advances, multiple myeloma (MM) remains a challenging, incurable, hematological malignancy. The efficacy of traditional chemotherapy and currently available anti-MM agents is in part limited by their adverse effects, which restrict their therapeutic potential. Nanotherapeutics is an emerging field of cancer therapy that can overcome the biological and chemical barriers of existing anticancer drugs. This review presents an overview of recent advancements in nanoparticle- and immunotherapy-based drug delivery systems for MM treatment. It further delves into the targeting strategies, mechanism of controlled drug release, and challenges associated with the development of drug delivery systems for the treatment of MM.

查看原文本刊更多论文

多发性骨髓瘤靶向给药系统的最新进展。

尽管在治疗方面取得了重大进展，但多发性骨髓瘤（MM）仍然是一种难以治愈的血液恶性肿瘤。传统化疗和现有抗多发性骨髓瘤药物的疗效部分受限于其不良反应，这限制了其治疗潜力。纳米疗法是一个新兴的癌症治疗领域，它可以克服现有抗癌药物的生物和化学障碍。本综述概述了用于 MM 治疗的基于纳米粒子和免疫疗法的给药系统的最新进展。它进一步深入探讨了治疗 MM 的靶向策略、药物控释机制以及与开发给药系统相关的挑战。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Controlled Release 医学-化学综合

CiteScore

18.50

自引率

5.60%

发文量

700

审稿时长

39 days

期刊介绍： The Journal of Controlled Release (JCR) proudly serves as the Official Journal of the Controlled Release Society and the Japan Society of Drug Delivery System. Dedicated to the broad field of delivery science and technology, JCR publishes high-quality research articles covering drug delivery systems and all facets of formulations. This includes the physicochemical and biological properties of drugs, design and characterization of dosage forms, release mechanisms, in vivo testing, and formulation research and development across pharmaceutical, diagnostic, agricultural, environmental, cosmetic, and food industries. Priority is given to manuscripts that contribute to the fundamental understanding of principles or demonstrate the advantages of novel technologies in terms of safety and efficacy over current clinical standards. JCR strives to be a leading platform for advancements in delivery science and technology.